Name
Session 9: Macrovascular Invasion : Balancing Systemic and Curative Options & Biomarkers, Liquid Biopsy: Guiding Precision Medicine in HCC
Date & Time
Thursday, October 23, 2025, 3:45 PM - 5:30 PM
Speakers
Shimul Shah , Mass General Brigham Chief, Division of Transplant Surgery As an academic multi-organ transplant and hepatobiliary surgeon with a special interest in translational and health services research at Mass General Brigham, Dr. Shimul A. Shah has strived for clinical excellence, innovation, and scholarship in the surgical arena. He was recently named Chief of Transplant Surgery and Clinical Director of the Transplant Center at Mass General Brigham returning to Boston from his training at Brigham and Women’s Hospital and early career in transplantation. Dr. Shah previously served as Director of Solid Organ Transplant at the University of Cincinnati.
Dr. Shah has a very busy clinical practice in liver, kidney and pancreas transplantation and a thriving hepatobiliary surgery practice specializing in the care of patients with end-stage liver disease, colorectal cancer metastases, biliary disorders and hepatocellular carcinoma. The UCMC liver transplant volume grew 330% since his arrival in late 2012, making it one of the most active program in the country with the highest transplant rate. He has focused on innovation and health equity and directed Cincinnati Research in Outcomes and Safety in Surgery (CROSS), a multidisciplinary group focused on health services research that has grown to include ten surgical faculty and a research team of over twenty students.
He holds leadership positions with the AHPBA and UNOS nationally. 
Augusto Villanueva , NYU Langone Health Medical Director, Liver Cancer Program Augusto Villanueva serves as the Medical Director of the Liver Cancer Program at NYU Langone Health in New York. He earned his medical degree from the University of Santiago de Compostela in Spain. His previous roles include Associate Professor in the Division of Liver Diseases at Mount Sinai Hospital and Senior Lecturer and Consultant Hepatologist at the Institute of Liver Studies at King’s College Hospital in London. Dr. Villanueva is a NIH-funded physician-scientist whose work integrates clinical practice as a hepatologist with research aimed at elucidating the role of intratumor heterogeneity in cancer evolution and developing innovative minimally invasive biomarkers through liquid biopsy. He has authored over 160 publications, accumulating more than 30,000 citations and an H-index of 72. His works have been featured in prestigious journals such as New England Journal of Medicine, Nature Genetics, Nature Biotechnology, Nature Communications, Gastroenterology, Hepatology, Journal of Hepatology, Gut, Journal of Clinical Investigation, and Oncogene. Dr. Villanueva is recognized among the top 1% most highly cited researchers for the years 2023 and 2024 by Clarivate. Additionally, he has contributed to more than 15 book chapters and edited a comprehensive volume on resistance to targeted therapies in hepatocellular carcinoma (HCC). He has held editorial positions as Associate Editor for the Journal of Hepatology and Liver Cancer, and has served as the Executive Secretary of the International Liver Cancer Association.
Augusto Villanueva , NYU Langone Health Medical Director, Liver Cancer Program Augusto Villanueva serves as the Medical Director of the Liver Cancer Program at NYU Langone Health in New York. He earned his medical degree from the University of Santiago de Compostela in Spain. His previous roles include Associate Professor in the Division of Liver Diseases at Mount Sinai Hospital and Senior Lecturer and Consultant Hepatologist at the Institute of Liver Studies at King’s College Hospital in London. Dr. Villanueva is a NIH-funded physician-scientist whose work integrates clinical practice as a hepatologist with research aimed at elucidating the role of intratumor heterogeneity in cancer evolution and developing innovative minimally invasive biomarkers through liquid biopsy. He has authored over 160 publications, accumulating more than 30,000 citations and an H-index of 72. His works have been featured in prestigious journals such as New England Journal of Medicine, Nature Genetics, Nature Biotechnology, Nature Communications, Gastroenterology, Hepatology, Journal of Hepatology, Gut, Journal of Clinical Investigation, and Oncogene. Dr. Villanueva is recognized among the top 1% most highly cited researchers for the years 2023 and 2024 by Clarivate. Additionally, he has contributed to more than 15 book chapters and edited a comprehensive volume on resistance to targeted therapies in hepatocellular carcinoma (HCC). He has held editorial positions as Associate Editor for the Journal of Hepatology and Liver Cancer, and has served as the Executive Secretary of the International Liver Cancer Association.
Description
Moderator: Shintaro Yagi Japan
Location Name
Meeting Room 1